Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

By Seino Yutaka   Nakajima Hiromu   Miyahara Hajime   Kurita Takashi   Bush Mark A.   Yang Fred   Stewart Murray W.    

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 3049-3057

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal‐L‐C randomized trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 335-343

John Wiley & Sons Inc

Access to resources Recommend Favorite

Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes

By Ross Stuart A.   Ballantine Jane  

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1617-1626

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of lixisenatide in elderly ( ≥65 years old) and very elderly ( ≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme

By  

DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol. 31, Iss. 2, 2015-02 ,pp. : 204-211

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of fasiglifam (TAK‐875), a G protein‐coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double‐blind, placebo‐controlled, phase III trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 675-681

John Wiley & Sons Inc

Access to resources Recommend Favorite